This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108:djv439.
Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.
Varade J, Magadan S, Gonzalez-Fernandez A. Human immunology and immunotherapy: main achievements and challenges. Cell Mol Immunol. 2021;18:805–28.
Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2021;20:332.
Mullard A. FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov. 2021;20:166.
Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021;18:792–804.
Dai X, Mei Y, Cai D, Han W. Standardizing CAR-T therapy: getting it scaled up. Biotechnol Adv. 2019;37:239–45.
Zhang C, Hu Y, Xiao W, Tian Z. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol. 2021;18:2083–100.
Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D. Driving the CAR to the bone marrow transplant program. Curr Hematol Malig Rep. 2019;14:561–9.
Han W, Fu X. Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General Hospital. Sci China Life Sci. 2016;59:1063–7.
Wei J, Liu Y, Wang C, Zhang Y, Tong C, Dai G, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020;5:134.
McGrath E, Chabannon C, Terwel S, Bonini C, Kuball J. Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. Curr Opin Oncol. 2020;32:427–33.
Acknowledgements
This work was supported by funds from the National Natural Science Foundation of China (No. 31991171, 81830002, 31870873, 81830006, and 81830004), the Science Technology Department of Zhejiang Province (No. 2021C03117) and the China Postdoctoral Science Foundation (No. 2021M690184 and 2021M690186).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Li, X., Dai, H., Li, X. et al. Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?. Cell Mol Immunol 19, 122–124 (2022). https://doi.org/10.1038/s41423-021-00789-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-021-00789-3